Case Details
- Citation: [2012] SGHC 35
- Case Title: Martek Biosciences Corporation v Cargill International Trading Pte Ltd
- Court: High Court of the Republic of Singapore
- Date of Decision: 16 February 2012
- Case Number: Originating Summons No 1418 of 2009
- Coram: Tay Yong Kwang J
- Judgment Reserved: Yes (judgment delivered on 16 February 2012)
- Judicial Role: Appeal from decision of IPOS tribunal (Deputy Registrar of Patents and Principal Assistant Registrar of Patents)
- Applicant/Plaintiff: Martek Biosciences Corporation
- Respondent/Defendant: Cargill International Trading Pte Ltd
- Legal Area: Patents and Inventions
- Patent at Issue: Singapore Patent No. 42669 (“the Patent”)
- Patent Title: “Arachidonic Acid and Methods for the Production and Use Thereof”
- Patent Grant Date: 30 March 1999
- Re-examination Trigger: IPOS Hearing Officers indicated intention to cause re-examination under s 80(2) of the Patents Act
- Re-examination Report: Dated 24 October 2008; made available to parties on 6 November 2008
- Tribunal Hearing Dates: 9 to 12 February 2009
- Statutes Referenced (as agreed): Evidence Act; Patents Act
- Evidence/Procedure: It was agreed that the Evidence Act (Cap 97, 1997 Rev Ed) and the Rules of Court (Cap 322, R5, 2006 Ed) would apply to the proceedings
- Key Patents Act Provisions Mentioned: s 80(1)(a); s 80(1)(c); s 80(2)
- Counsel for Applicant: Dr Stanley Lai, SC and Vignesh Vaerhn (Allen & Gledhill LLP)
- Counsel for Respondent: Daniel Koh (instructed) (Eldan Law LLP) and Wendy Low Wei Ling (Rajah & Tann LLP)
- Witnesses (Respondent’s experts below): Dr Puah Chum Mok; Dr Nga Been Hen
- Related Prior Litigation: Martek Biosciences Corporation v Cargill International Trading [2011] 4 SLR 429 (“Martek v Cargill (No 1)”) concerning another patent (Singapore Patent P-No. 49307)
- Judgment Length: 17 pages; 9,840 words (as stated in metadata)
Summary
This High Court decision concerns an appeal by Martek Biosciences Corporation (“Martek”) against an IPOS tribunal’s decision revoking Martek’s Singapore Patent No. 42669. The tribunal had allowed Cargill International Trading Pte Ltd (“Cargill”) to revoke the patent on grounds that the claimed invention was not patentable and that the patent specification was insufficient. The appeal was heard by Tay Yong Kwang J, who ultimately allowed Martek’s appeal and dismissed Cargill’s appeal insofar as it related to certain aspects of the tribunal’s decision.
Although the judgment is technical—centred on the production of arachidonic acid (“ARA”) oils using microbial cultivation and the desired ARA-to-eicosapentaneoic acid (“EPA”) ratios—the legal analysis turns on classic patent validity questions under the Patents Act. The court’s approach reflects the evidential and doctrinal discipline required in patent revocation proceedings: the court scrutinises expert evidence, evaluates whether the prior art anticipates the claims or renders them not patentable, and assesses whether the specification enables the skilled person to carry out the invention.
What Were the Facts of This Case?
Martek is the proprietor of the patent entitled “Arachidonic Acid and Methods for the Production and Use Thereof”, granted by IPOS on 30 March 1999. The patent addresses processes for producing arachidonic acid-containing oils, with an emphasis on obtaining oils preferably free of eicosapentaneoic acid. The invention also relates to compositions containing very high amounts of arachidonic acid in triglyceride form, and to uses of such oils, particularly as additives for infant formula.
The patent’s technical premise is that arachidonic acid is an omega-6 long chain polyunsaturated fatty acid important for human metabolism, but cannot be synthesised de novo in humans. Consequently, ARA must be supplied through diet, especially during infancy when growth is rapid. Human breast milk contains high levels of ARA and is a prevalent source of C20 PUFA. However, not all infants are breastfed; therefore, there is a need for an economical method to produce ARA for infant formula.
Martek’s patent identifies a problem in the prior art: many fungal species that produce ARA also produce significant quantities of EPA. High EPA levels in dietary supplements can depress the ability to form ARA from linoleic acid. The patent therefore aims to provide microbial oils with sufficient ARA while achieving a high ARA:EPA ratio. The patent contemplates achieving ratios such as at least 5:1, preferably at least 10:1, and ideally around 20:1, with higher ARA relative to EPA being more desirable.
Procedurally, Cargill filed an application to revoke the patent on 20 January 2006. It relied on two main grounds: first, that the invention was not patentable under s 80(1)(a) of the Patents Act; and second, that the patent was insufficient under s 80(1)(c) because the specification did not disclose the invention clearly and completely for it to be performed by a person skilled in the art. Martek responded by applying to amend the claims on 6 September 2006. The amendments were advertised in the Patents Journal on 30 October 2006 and were not opposed; the tribunal held them allowable because they did not add matter or extend protection. The revocation proceedings therefore proceeded on the basis of the amended claims.
At a case management conference on 28 April 2008, IPOS hearing officers indicated that the patent would be re-examined under s 80(2). Cargill filed the request for re-examination, and the patent was re-examined by an examiner from the Australian Patent Office of IP Australia. A re-examination report dated 24 October 2008 was made available to the parties on 6 November 2008. The tribunal then heard the matter from 9 to 12 February 2009. The parties agreed that the Evidence Act and the Rules of Court would apply to the proceedings.
What Were the Key Legal Issues?
The appeal required the High Court to consider whether the tribunal was correct in allowing revocation of the patent. The legal issues were framed by the grounds pleaded under the Patents Act. In particular, the court had to determine whether the invention was “not a patentable invention” within the meaning of s 80(1)(a). This typically involves assessing novelty and/or inventive step in light of the prior art, and whether the claimed subject matter is sufficiently distinct from what was already known.
The second issue was insufficiency under s 80(1)(c). The question here is whether the patent specification discloses the invention clearly and completely enough for a person skilled in the art to carry it out. In technical patents, insufficiency often turns on whether the specification provides workable guidance on key parameters, processes, and outcomes—particularly where the invention depends on achieving specific compositional ratios or product characteristics.
In addition, because this was the second appeal in a related patent dispute between the same parties, the court’s reasoning also had to be consistent with its earlier approach in Martek v Cargill (No 1) concerning another patent. While the present case concerned a different Singapore patent, the court’s treatment of evidence, claim construction, and validity analysis would inevitably be informed by the earlier litigation’s procedural and substantive context.
How Did the Court Analyse the Issues?
The court began by setting out the procedural posture and the relationship to the earlier case. Tay Yong Kwang J emphasised that this appeal was against the tribunal’s decision revoking Singapore Patent No. 42669. He also noted that this was the second appeal by Martek from IPOS decisions. The first appeal had concerned another patent (Singapore Patent P-No. 49307), and the High Court had delivered judgment in Martek v Cargill (No 1). This background mattered because it shaped the court’s understanding of the parties’ technical positions and the evidential record.
A significant early part of the judgment addressed expert evidence. The applicant challenged the respondent’s expert, Dr Puah Chum Mok, on multiple grounds, including alleged lack of relevant expertise, evidence outside his area of specialisation, and unreliability of his statutory declarations. The tribunal had expressed caution about Dr Puah’s evidence and found that he did not appear to possess the relevant expertise to assist confidently on the matters in question. The applicant urged the High Court to disregard Dr Puah’s evidence entirely. However, the High Court declined to go that far. Tay Yong Kwang J observed that the tribunal did not rely on Dr Puah’s evidence for its findings, and the respondent confirmed before the High Court that it was not relying on Dr Puah’s evidence, relying instead on Dr Nga Been Hen’s evidence and the objective text of the prior art.
This evidential discussion is legally important because patent revocation proceedings often hinge on expert interpretation of technical documents and on whether the skilled person would find the claimed invention disclosed or rendered obvious by the prior art. By clarifying that the tribunal did not rely on Dr Puah, the court reduced the risk that the applicant’s appeal would succeed merely on an evidential defect. Instead, the court focused on whether the tribunal’s substantive conclusions on patentability and sufficiency were correct.
On the substantive validity analysis, the court identified the prior art documents cited before the tribunal as D1 to D10, with D1, D4, D7 and D10 assuming particular significance. D1 was “Production of Arachidonic Acid by Mortierella alpina ATCC 3222” (Bajpai et al, 1991). D4 was Japanese Patent No. 64-38007, translated as “External Preparation for Skin”. D7 was WO 92/13086 titled “Arachidonic Acid and methods of the production and use thereof” (1992). D10 was WO 94/28913 concerning methods and pharmaceutical compositions useful for treating neurological disorders. The court indicated that it would analyse these documents when addressing validity.
Although the provided extract truncates the remainder of the judgment, the structure and issues indicate that the court’s analysis would have followed a standard patent revocation framework: (i) interpret the amended claims; (ii) compare the claimed subject matter against the disclosure of the prior art; (iii) determine whether the invention was novel and/or involved an inventive step; and (iv) assess whether the specification enabled the skilled person to carry out the invention. In technical cases involving biological processes and compositional targets, claim construction and the identification of the “essential” features of the invention are crucial. The patent’s emphasis on achieving high ARA:EPA ratios, and on producing triglyceride oils suitable for infant formula, would likely have been treated as central to the claimed invention.
For insufficiency, the court would have considered whether the specification provided sufficient information about cultivation conditions, selection of microbial species, extraction and recovery steps, and how to achieve the desired triglyceride oil composition. The patent’s description of preferred embodiments—such as cultivating Mortierella alpina under conditions yielding triglyceride oil with particularly high levels of ARA residues—suggests that the specification attempts to guide the skilled person toward the targeted compositional outcome. The legal question is whether those teachings are clear and complete, or whether the skilled person would need undue experimentation or would not be able to reproduce the claimed results.
What Was the Outcome?
The High Court allowed Martek’s appeal against the tribunal’s decision revoking the patent. In practical terms, this means that the revocation order made by the IPOS tribunal was not upheld, and Martek’s Singapore Patent No. 42669 remained in force (subject to any limited aspects of the tribunal’s decision that were not disturbed).
The court also dismissed Cargill’s appeal insofar as it related to certain aspects of the tribunal’s decision. This indicates that while the respondent may have succeeded on some narrower points below, the overall revocation outcome could not stand in light of the High Court’s assessment of the legal and evidential issues.
Why Does This Case Matter?
Martek v Cargill (No 2) is significant for practitioners because it illustrates how the High Court approaches IPOS tribunal decisions in patent revocation matters. The case underscores that appellate review is not merely a re-hearing of technical evidence; it involves careful scrutiny of whether the tribunal correctly applied the Patents Act standards for patentability and sufficiency.
From an evidential perspective, the judgment highlights the importance of expert testimony quality and relevance. Where an expert is found to lack the relevant expertise, the court will consider whether the tribunal relied on that evidence. The decision therefore serves as a reminder that expert evidence must be both competent and properly tethered to the technical questions the tribunal must decide.
Substantively, the case is also useful for understanding how courts deal with patents whose claims depend on achieving specific biochemical or compositional outcomes. For such inventions, insufficiency arguments often focus on whether the specification enables the skilled person to reproduce the claimed results. Conversely, patentability arguments often focus on whether prior art disclosures already teach the same process parameters and product characteristics, or whether the claimed combination is sufficiently distinct. Lawyers advising on patent prosecution, amendment strategy, and enforcement should take note of how claim amendments (advertised and unopposed) can shape the validity analysis, and how the court’s focus remains on the amended claims actually in issue.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), including:
- Section 80(1)(a)
- Section 80(1)(c)
- Section 80(2)
- Evidence Act (Cap 97, 1997 Rev Ed)
- Rules of Court (Cap 322, R5, 2006 Ed)
Cases Cited
- Martek Biosciences Corporation v Cargill International Trading [2011] 4 SLR 429 (“Martek v Cargill (No 1)”)
- [2012] SGHC 35 (the present case)
Source Documents
This article analyses [2012] SGHC 35 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.